Evaluation of intravenous Topotecan + Cisplatin as a potential new standard of care in 1st line Small Cell Lung Cancer

Inclusion Criteria:

• Evaluable extensive small cell lung cancer, extensive disease.
• Eastern Cooperative Oncology Group (ECOG) performance status < 2.
• Life expectancy > 3 months.
• Fit to receive any of the treatments.
• No prior chemotherapy.
• Written informed consent.

Exclusion Criteria:

• Extensive disease treatable with radiotherapy.
• Past or current history of other malignant disease.
• Prior chemotherapy.
• Pregnancy, lactating or lack of effective contraception.
• Concurrent severe medical problems other than small cell lung cancer.
• Patients with central nervous system metastases receiving more than 12 mg /day dexamethasone or equivalent to control symptoms.